PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Participate in Upcoming Investor Conferences
PDL BioPharma Completes Regular Quarterly Dividend Payment
PDL BioPharma Provides Second Quarter 2014 Revenue Guidance of $140 Million
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PDL BioPharma to Present at Jefferies 2014 Global Healthcare Conference